BioNTech (NASDAQ:BNTX) Stock Gets Price Target Cut from HC Wainwright

BioNTech (NASDAQ:BNTX) had its target price reduced by HC Wainwright from $130.00 to $110.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company reduced their price target on BioNTech from $140.00 to $125.00 and set an “overweight” rating on the stock in a report on Wednesday, November 4th. Bank of America restated a “buy” rating on shares of BioNTech in a report on Wednesday, November 4th. Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. UBS Group cut their price objective on BioNTech from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Finally, Citigroup reduced their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.27.

BioNTech Stock Up 0.5%

Shares of NASDAQ BNTX opened at $87.65 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.55 and a quick ratio of 8.52. The company has a market cap of $22.17 billion, a P/E ratio of -12.80 and a beta of 1.28. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm has a 50-day simple moving average of $93.80 and a two-hundred day simple moving average of $96.25.

Insider Activity at BioNTech

In other news, CEO Ugur Sahin sold 72,000 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the transaction, the chief executive officer directly owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. This trade represents a 39.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock worth $79,246,837 over the last 90 days. Company insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in BioNTech during the 2nd quarter valued at $39,000. Farther Finance Advisors LLC grew its position in shares of BioNTech by 31.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after buying an additional 118 shares in the last quarter. Parallel Advisors LLC grew its position in shares of BioNTech by 50.3% during the 3rd quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock worth $83,000 after buying an additional 282 shares in the last quarter. Quintet Private Bank Europe S.A. grew its position in shares of BioNTech by 232.8% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after buying an additional 1,341 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of BioNTech during the first quarter valued at $220,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.